Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis

The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lymphoma Hemic and Lymphatic Diseases Hemophagocytic Lymphohistiocytoses Histiocytosis Histiocytosis, Non-Langerhans-Cell Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphohistiocytosis, Hemophagocytic Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States

Location status: Recruiting

Location contact

Gaurav Goyal, MD

CONTACT

[email protected]

2059346770

About this study

Retrospective, multi-institutional study focused on describing the clinical features, laboratory parameters, treatments, and outcomes among individuals presenting with HLH in the setting of a lymphoma

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with lymphoma that are fulfilling at least one of the following:

A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25>3,900 U/mL and ferritin>1,000 ng/mL)

Exclusion criteria

Patients developing HLH> 1 month after lymphoma diagnosis (for aggressive lymphomas)
Patients with incomplete treatment and response documentation

Treatment and study plan

Primary outcomes

To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+

Time frame: The participant's survival would be assessed at 180 days from the malignancy diagnosis

The investigators will gather data on different treatments received, time to treatment, and other factors and determine which is associated with survival.

Study contacts

Contact information is provided by the study sponsor or research team.

Gaurav Goyal, MD

CONTACT

[email protected]

205-934-1816

Sponsors and collaborators

Lead sponsor

University of Alabama at Birmingham

Other

Registry information

Important dates

Study start: 2023
Primary completion: 2028
Study completion: 2028
First posted: Jun 12, 2023
Registry last updated: Jan 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting